Evidence map›Paper›PMID 31221545›Full record

ArticleClinical genitourinary cancer2019

Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.

Alison R Roth, Stephanie A Harmon, Timothy G Perk, Jens Eickhoff, Peter L Choyke, Karen A Kurdziel, William L Dahut, Andrea B Apolo, Michael J Morris, Scott B Perlman and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. The Prostate · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Alison R RothDepartment of Medical Physics, University of Wisconsin, Madison, WI. Electronic address: aroth5@wisc.edu.
Stephanie A HarmonDepartment of Medical Physics, University of Wisconsin, Madison, WI.
Timothy G PerkDepartment of Medical Physics, University of Wisconsin, Madison, WI.
Jens EickhoffDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI.
Peter L ChoykeMolecular Imaging Branch, National Cancer Institute, Bethesda, MD.
Karen A KurdzielMolecular Imaging Branch, National Cancer Institute, Bethesda, MD.
William L DahutGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.
Andrea B ApoloGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.
Michael J MorrisMemorial Sloan Kettering Cancer Center, New York, NY.
Scott B PerlmanUniversity of Wisconsin Carbone Cancer Center, Madison, WI.
Glenn LiuDepartment of Medical Physics, University of Wisconsin, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI.
Robert JerajDepartment of Medical Physics, University of Wisconsin, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI.
University of Wisconsin–Madison · USNational Cancer Institute · USMemorial Sloan Kettering Cancer Center · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
U.W. RADIOLOGICAL SCIENCES TRAINING PROGRAMT32CA009206 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Bryan Patrick Bednarz · 1985 to 2026
$12.1M
Intramural NIH HHS ZIA BC010655NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014520NCI NIH HHS T32 CA009206
6 · The paper itself

Abstract

backgroundWhole-body assessments of PATIENTS AND

methodsFifty-four mCRPC patients with osseous metastases received baseline NaF PET/CT. Patients received chemotherapy (n = 16) or androgen receptor pathway inhibitors (n = 38). Semiautomated analysis using Quantitative Total Bone Imaging software extracted imaging metrics for the whole, axial, and appendicular skeleton as well as 11 skeletal regions. Five PET metrics were extracted for each region: number of lesions (N

resultsThe strongest univariate models of progression-free survival were pelvic N

conclusionQuantitative characterization of metastatic spread by anatomic location on NaF PET/CT enhances potential prognostication. Further study is warranted to optimize the prognostic and predictive value of NaF PET/CT in mCRPC patients.

Indexed as

Antineoplastic AgentsBone NeoplasmsFluorine RadioisotopesHumansMalePositron Emission Tomography Computed TomographyPrognosisProstatic Neoplasms, Castration-ResistantSodium FluorideSurvival AnalysisTreatment OutcomeAntineoplastic AgentsFluorine-18Fluorine RadioisotopesSodium FluorideDistributionMulticenter clinical trialPETSodium fluoride

Identifiers

PMID31221545
PMCPMC7331881
OpenAlexW2946854127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.